Most patients lose initial gains in vision despite continued treatment, he added. In a 2022 study, Sodhi’s group identified ...

The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

A Johns Hopkins study reveals that anti-VEGF treatments for wet AMD may unintentionally elevate ANGPTL4, a protein that ...

Summit and Akeso's ivonescimab attracted headlines earlier this year when it was shown to be more effective than anti-PD-1 ...

Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think ...

Study points to approach to improving anti-VEGF therapy for all wet AMD patients, and help subset of patients who lose vision ...

The BRIGHT trial will evaluate HG202's safety, efficacy, and potential to improve visual acuity and reduce anti-VEGF ...

A study from researchers at Wilmer Eye Institute, Johns Hopkins Medicine explains not only why some patients with wet ...

The vessels leak fluid or bleed, damaging the retina and causing vision loss. To combat this, doctors prescribe medications ...

AlloVir has been reeling ever since a trio of phase 3 trial failures last year led the company to shed almost all of its staff. | AlloVir has been reeling after a trio of phase 3 trial failures last ...

Advertisement To combat this, doctors prescribe medications that slow the growth of new blood vessels, called anti-VEGF (vascular endothelial growth factor) drugs. Unfortunately, these anti-VEGF ...